Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin vs Tiotropium in COPD with Suboptimal PIFR (PIFR-2)
NCT05165485Phase 4Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Theravance Biopharma, Inc.. Started Jan 2022; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05165485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165485.